PURPOSE: This phase I study of high dose ketoconazole and docetaxel was designed against castration resistant prostate cancer to determine the maximum tolerated doses, side effects, and pharmacokinetic interaction of co-administered docetaxel and ketoconazole. MATERIALS AND METHODS: Patients with metastatic castration resistant prostate cancer received weekly docetaxel for 3 of every 4 weeks plus daily ketoconazole. Pharmacokinetic studies were performed on day 1 (docetaxel alone) and day 16 (after ketoconazole). RESULTS: The study enrolled 42 patients at 9 different dose levels. The combination regimens investigated included docetaxel weekly, increasing from 5 to 43 mg/m(2), with starting doses of 600, 800 or 1,200 mg ketoconazole daily. Decreases in prostate specific antigen of 50% or greater were seen in 62% of patients. Of 25 patients with soft tissue disease 7 (28%) had a partial response. Median overall survival was 22.8 months and was significantly greater in docetaxel naïve patients than in patients pretreated with docetaxel (36.8 vs 10.3 months, p = 0.0001). The most frequently observed adverse events were anemia, edema, fatigue, diarrhea, nausea, sensory neuropathy and elevated liver function tests. The fractional change in docetaxel clearance correlated significantly with ketoconazole exposure (p <0.01). Concomitant ketoconazole increased docetaxel exposure 2.6-fold with 1,200 mg daily, 1.6-fold with 800 mg daily and approximately 1.3 to 1.5-fold with 600 mg daily. CONCLUSIONS: Combination regimens using 600 mg ketoconazole daily were fairly well tolerated and the maximum tolerated dose of docetaxel was 32 mg/m(2). Results suggest that the combination has significant antitumor activity in castration resistant prostate cancer. The long survival in the docetaxel naïve cohort warrants additional, larger trials of docetaxel with ketoconazole or possibly CYP17A1 inhibitors such as abiraterone. Copyright 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
PURPOSE: This phase I study of high dose ketoconazole and docetaxel was designed against castration resistant prostate cancer to determine the maximum tolerated doses, side effects, and pharmacokinetic interaction of co-administered docetaxel and ketoconazole. MATERIALS AND METHODS:Patients with metastatic castration resistant prostate cancer received weekly docetaxel for 3 of every 4 weeks plus daily ketoconazole. Pharmacokinetic studies were performed on day 1 (docetaxel alone) and day 16 (after ketoconazole). RESULTS: The study enrolled 42 patients at 9 different dose levels. The combination regimens investigated included docetaxel weekly, increasing from 5 to 43 mg/m(2), with starting doses of 600, 800 or 1,200 mg ketoconazole daily. Decreases in prostate specific antigen of 50% or greater were seen in 62% of patients. Of 25 patients with soft tissue disease 7 (28%) had a partial response. Median overall survival was 22.8 months and was significantly greater in docetaxel naïve patients than in patients pretreated with docetaxel (36.8 vs 10.3 months, p = 0.0001). The most frequently observed adverse events were anemia, edema, fatigue, diarrhea, nausea, sensory neuropathy and elevated liver function tests. The fractional change in docetaxel clearance correlated significantly with ketoconazole exposure (p <0.01). Concomitant ketoconazole increased docetaxel exposure 2.6-fold with 1,200 mg daily, 1.6-fold with 800 mg daily and approximately 1.3 to 1.5-fold with 600 mg daily. CONCLUSIONS: Combination regimens using 600 mg ketoconazole daily were fairly well tolerated and the maximum tolerated dose of docetaxel was 32 mg/m(2). Results suggest that the combination has significant antitumor activity in castration resistant prostate cancer. The long survival in the docetaxel naïve cohort warrants additional, larger trials of docetaxel with ketoconazole or possibly CYP17A1 inhibitors such as abiraterone. Copyright 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Authors: Tessa M Bosch; Alwin D R Huitema; Valerie D Doodeman; Robert Jansen; Els Witteveen; Wim M Smit; Rob L Jansen; Carla M van Herpen; Marcel Soesan; Jos H Beijnen; Jan H M Schellens Journal: Clin Cancer Res Date: 2006-10-01 Impact factor: 12.531
Authors: Frederike K Engels; Walter J Loos; Ron A A Mathot; Ron H N van Schaik; Jaap Verweij Journal: Cancer Chemother Pharmacol Date: 2007-01-26 Impact factor: 3.333
Authors: Frederike K Engels; Ron A A Mathot; Walter J Loos; Ron H N van Schaik; Jaap Verweij Journal: Cancer Biol Ther Date: 2006-07-22 Impact factor: 4.742
Authors: Erin R Lepper; Sharyn D Baker; Matt Permenter; Nicole Ries; Ron H N van Schaik; Paul W Schenk; Douglas K Price; Danielle Ahn; Nicola F Smith; George Cusatis; Roxann G Ingersoll; Susan E Bates; Ron H J Mathijssen; Jaap Verweij; William D Figg; Alex Sparreboom Journal: Clin Cancer Res Date: 2005-10-15 Impact factor: 12.531
Authors: Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Michael J Thun Journal: CA Cancer J Clin Date: 2007 Jan-Feb Impact factor: 508.702
Authors: Mary B Wire; Charles H Ballow; Julie Borland; Mark J Shelton; Yu Lou; Geoffrey Yuen; Jiang Lin; Eric W Lewis Journal: Antimicrob Agents Chemother Date: 2007-05-21 Impact factor: 5.191
Authors: Prashanth K B Nagesh; Nia R Johnson; Vijaya K N Boya; Pallabita Chowdhury; Shadi F Othman; Vahid Khalilzad-Sharghi; Bilal B Hafeez; Aditya Ganju; Sheema Khan; Stephen W Behrman; Nadeem Zafar; Subhash C Chauhan; Meena Jaggi; Murali M Yallapu Journal: Colloids Surf B Biointerfaces Date: 2016-03-26 Impact factor: 5.268
Authors: Aura D Herrera-Martínez; Richard A Feelders; Wouter W de Herder; Justo P Castaño; María Ángeles Gálvez Moreno; Fadime Dogan; Rosanna van Dungen; Peter van Koetsveld; Leo J Hofland Journal: Horm Cancer Date: 2019-05-18 Impact factor: 3.869
Authors: Richard E Kast; John A Boockvar; Ansgar Brüning; Francesco Cappello; Wen-Wei Chang; Boris Cvek; Q Ping Dou; Alfonso Duenas-Gonzalez; Thomas Efferth; Daniele Focosi; Seyed H Ghaffari; Georg Karpel-Massler; Kirsi Ketola; Alireza Khoshnevisan; Daniel Keizman; Nicolas Magné; Christine Marosi; Kerrie McDonald; Miguel Muñoz; Ameya Paranjpe; Mohammad H Pourgholami; Iacopo Sardi; Avishay Sella; Kalkunte S Srivenugopal; Marco Tuccori; Weiguang Wang; Christian R Wirtz; Marc-Eric Halatsch Journal: Oncotarget Date: 2013-04